Entity
Description
  • Value proposition

    Biomorphic Programmable Polymers

    TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.

    Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.

    Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.

    We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

    Medical Device, MedTech, Synthetic Polymers, Tissue Reconstruction, and Innovation

  • Original language

    Biomorphic Programmable Polymers

    TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.

    Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.

    Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.

    We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

  • Tissue Reconstruction Solutions | TISSIUM Biomorphic Programmable Polymers

    TISSIUM is creating the future of tissue reconstruction. Learn more about our novel solutions based on our proprietary platform of biomorphic programmable polymers.

  • https://tissium.com/
Corporate interactions BETA
Corporate TypeTweets Articles
La French Tech Bourgogne-Franche-Comté
La French Tech Bourgogne-Franche-Comté
French Tech, Non-profit Organizations
La French Tech Bourgogne-Franche-Comté
French Tech, Non-profit Organizations
Other

2 Sep 2024


Crédit Mutuel
Crédit Mutuel
Bank, Banking
Crédit Mutuel
Bank, Banking
Other

18 Jul 2024


Start Industrie
Start Industrie
Non-profit Organizations
Start Industrie
Non-profit Organizations
Other

22 May 2024


Institut Curie
Institut Curie
Health, Hospitals and Health Care
Institut Curie
Health, Hospitals and Health Care
Other

19 Nov 2023


KLESIA
KLESIA
Insurance
KLESIA
Insurance
Other

12 Jun 2023

13 Jul 2023



CMA CGM
CMA CGM
Transportation, Logistics, Supply Chain and Storage
CMA CGM
Transportation, Logistics, Supply Chain and Storage
Other

16 Apr 2023


Ministry of Economy
Ministry of Economy
Government Administration
Ministry of Economy
Government Administration
Other

22 Feb 2023


Karista
Karista
Startup accelerator & VC, Venture Capital and Private Equity Principals
Karista
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

23 May 2024


PYMNTS
PYMNTS
Online Audio and Video Media
PYMNTS
Online Audio and Video Media
Other

21 Aug 2022


Eurasanté
Eurasanté
Startup accelerator & VC, Biotechnology, Biotechnology Research
Eurasanté
Startup accelerator & VC, Biotechnology, Biotechnology Research
Other

10 Oct 2022


Similar entities
Loading...
Loading...
Social network dynamics